• Winter Storm Watch - Click for Details
    ...WINTER STORM WATCH IN EFFECT FROM WEDNESDAY MORNING THROUGH LATE WEDNESDAY NIGHT...
    Effective: February 12, 2025 @ 6:00am
    Expires: February 13, 2025 @ 3:00am
    WHAT
    Heavy snow possible. Total snow accumulations between 6 and 8 inches possible.
    WHERE
    Portions of north central, northwest, and west central Illinois and east central, northeast, and southeast Iowa.
    WHEN
    From Wednesday morning through late Wednesday night.
    IMPACTS
    Travel could be very difficult. The hazardous conditions could impact the Wednesday morning and evening commutes.
    ADDITIONAL DETAILS
    North winds 10 to 15 mph, with gusts up 25 mph may cause some blowing and drifting snow, especially on east-west roads.
    PRECAUTIONARY/PREPAREDNESS ACTIONS
    Monitor the latest forecasts for updates on this situation.

US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain

SHARE NOW

By Ahmed Aboulenein and Amina Niasse

WASHINGTON (Reuters) – The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S. Federal Trade Commission said on Tuesday.

From 2017 to 2022, the companies — UnitedHealth Group’s Optum, CVS Health’s CVS Caremark and Cigna’s Express Scripts — marked up prices at their affiliated pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue in excess of the acquisition costs of the drugs, the FTC said in its second report on the industry.

Pharmacy benefit managers, or PBMs, act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions.

The FTC sued the three PBMs in September, accusing them of steering diabetes patients toward higher priced insulin products in order to reap millions of dollars in rebates from drugmakers. The companies say the suit is baseless and defend their practices.

(Reporting by Ahmed Aboulenein in Washington and Amina Niasse in New York; Editing by Bill Berkrot)

Brought to you by www.srnnews.com

Submit a Comment